fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

European Commission approves Durveqtix (fidanacogene elaparvovec), a one-time gene therapy for adults with hemophilia B – Pfizer

Written by | 1 Aug 2024

Pfizer Inc. announced that the European Commission (EC) has granted conditional marketing authorization for Durveqtix (fidanacogene elaparvovec), a gene therapy for the treatment of severe and moderately severe… read more.

CHMP positive recommendation for Durveqtix (fidanacogene elaparvovec) to treat haemophilia B – Pfizer

Written by | 9 Jun 2024

The Committee for Medicinal Products for Human Use (CHMP) has recommended granting conditional marketing authorization in the EU to Pfizer’s hemophilia B gene therapy Durveqtix (fidanacogene elaparvovec). Durveqtix,… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.